Faced with a looming cash crisis, Pharmexa A/S priced a long-expected rights issue. The Hørsholm, Denmark-based immunotherapy firm said it would offer shareholders up to about 12.3 million new shares at DKK17 per share, almost 50 percent below Monday's closing share price of DKK31.70. (BioWorld International)

Faced with a looming cash crisis, Pharmexa A/S priced a long-expected rights issue. The Hørsholm, Denmark-based immunotherapy firm said it would offer shareholders up to about 12.3 million new shares at DKK17 per share, almost 50 percent below Monday's closing share price of DKK31.70. (BioWorld International)